<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>65(3)</volume><submitter>Sautto GA</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>The recent availability of novel antiviral drugs has raised new hope for a more effective treatment of hepatitis C virus (HCV) infection and its severe sequelae. However, in the case of non-responding or relapsing patients, alternative strategies are needed. To this end we have used chimeric antigen receptors (CARs), a very promising approach recently used in several clinical trials to redirect primary human T cells against different tumours. In particular, we designed the first CARs against HCV targeting the HCV/E2 glycoprotein (HCV/E2).&lt;h4>Design&lt;/h4>Anti-HCV/E2 CARs were composed of single-chain variable fragments (scFvs) obtained from a broadly cross-reactive and cross-neutralising human monoclonal antibody (mAb), e137, fused to the intracellular signalling motif of t</pubmed_abstract><journal>Gut</journal><pagination>512-23</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4789830</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.</pubmed_title><pmcid>PMC4789830</pmcid><pubmed_authors>Sautto GA</pubmed_authors><pubmed_authors>Protzer U</pubmed_authors><pubmed_authors>Diotti RA</pubmed_authors><pubmed_authors>Burioni R</pubmed_authors><pubmed_authors>Graf J</pubmed_authors><pubmed_authors>Mancini N</pubmed_authors><pubmed_authors>Wisskirchen K</pubmed_authors><pubmed_authors>Clementi N</pubmed_authors><pubmed_authors>Castelli M</pubmed_authors><pubmed_authors>Clementi M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.</name><description>&lt;h4>Objective&lt;/h4>The recent availability of novel antiviral drugs has raised new hope for a more effective treatment of hepatitis C virus (HCV) infection and its severe sequelae. However, in the case of non-responding or relapsing patients, alternative strategies are needed. To this end we have used chimeric antigen receptors (CARs), a very promising approach recently used in several clinical trials to redirect primary human T cells against different tumours. In particular, we designed the first CARs against HCV targeting the HCV/E2 glycoprotein (HCV/E2).&lt;h4>Design&lt;/h4>Anti-HCV/E2 CARs were composed of single-chain variable fragments (scFvs) obtained from a broadly cross-reactive and cross-neutralising human monoclonal antibody (mAb), e137, fused to the intracellular signalling motif of t</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Mar</publication><modification>2026-05-05T17:37:29.157Z</modification><creation>2019-03-26T22:42:35Z</creation></dates><accession>S-EPMC4789830</accession><cross_references><pubmed>25661083</pubmed><doi>10.1136/gutjnl-2014-308316</doi></cross_references></HashMap>